Cargando…
Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15–30). Mont...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222015/ https://www.ncbi.nlm.nih.gov/pubmed/33713213 http://dx.doi.org/10.1007/s10461-021-03205-z |
_version_ | 1783711422491918336 |
---|---|
author | Mayo, Ashley J. Browne, Erica N. Montgomery, Elizabeth T. Torjesen, Kristine Palanee-Phillips, Thesla Jeenarain, Nitesha Seyama, Linly Woeber, Kubashni Harkoo, Ishana Reddy, Krishnaveni Tembo, Tchangani Mutero, Prisca Tauya, Thelma Chitukuta, Miria Gati Mirembe, Brenda Soto-Torres, Lydia Brown, Elizabeth R. Baeten, Jared M. van der Straten, Ariane |
author_facet | Mayo, Ashley J. Browne, Erica N. Montgomery, Elizabeth T. Torjesen, Kristine Palanee-Phillips, Thesla Jeenarain, Nitesha Seyama, Linly Woeber, Kubashni Harkoo, Ishana Reddy, Krishnaveni Tembo, Tchangani Mutero, Prisca Tauya, Thelma Chitukuta, Miria Gati Mirembe, Brenda Soto-Torres, Lydia Brown, Elizabeth R. Baeten, Jared M. van der Straten, Ariane |
author_sort | Mayo, Ashley J. |
collection | PubMed |
description | We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15–30). Monthly returned rings were classified as nonadherent if dapivirine release rate was ≤ 0.9 mg/month. Associations between acceptability measures and nonadherence were estimated using Poisson regression models with robust standard errors. At month 3 (N = 2334), 88% reported DVR was comfortable, 80% were unaware of it during daily activities, and 74% never felt it during sex. At exit, 66% were ‘very likely’ to use DVR in the future. Acceptability was found to differ significantly by country across several measures including wearing the ring during sex, during menses, partner acceptability, impact on sexual pleasure and willingness to use the ring in the future. Risk of nonadherence at month 12 was elevated if DVR was felt during sex at month 3 (aRR 1.67, 95% CI 1.26, 2.23). Risk of nonadherence in the last year of study participation was elevated if, at exit, participants minded wearing during sex (aRR 2.08, 95% CI 1.52, 2.85), during menses (aRR 1.57, 95% CI 1.06, 2.32), reported a problematic change to the vaginal environment (aRR 1.57, 95% CI 1.12, 2.21), and were not “very likely” to use DVR in the future (aRR 1.31, 95% CI 1.02, 1.68). DVR acceptability was overall high yet varied by country. Addressing perceived ring interference with sex, menses, or problematic changes to the vaginal environment in future interventions could help improve adherence, as could embracing sex-positive messaging related to ring use and increased pleasure. Trial Registration ClinicalTrials.gov Identifier: NCT01617096. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10461-021-03205-z. |
format | Online Article Text |
id | pubmed-8222015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-82220152021-06-28 Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial Mayo, Ashley J. Browne, Erica N. Montgomery, Elizabeth T. Torjesen, Kristine Palanee-Phillips, Thesla Jeenarain, Nitesha Seyama, Linly Woeber, Kubashni Harkoo, Ishana Reddy, Krishnaveni Tembo, Tchangani Mutero, Prisca Tauya, Thelma Chitukuta, Miria Gati Mirembe, Brenda Soto-Torres, Lydia Brown, Elizabeth R. Baeten, Jared M. van der Straten, Ariane AIDS Behav Original Paper We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15–30). Monthly returned rings were classified as nonadherent if dapivirine release rate was ≤ 0.9 mg/month. Associations between acceptability measures and nonadherence were estimated using Poisson regression models with robust standard errors. At month 3 (N = 2334), 88% reported DVR was comfortable, 80% were unaware of it during daily activities, and 74% never felt it during sex. At exit, 66% were ‘very likely’ to use DVR in the future. Acceptability was found to differ significantly by country across several measures including wearing the ring during sex, during menses, partner acceptability, impact on sexual pleasure and willingness to use the ring in the future. Risk of nonadherence at month 12 was elevated if DVR was felt during sex at month 3 (aRR 1.67, 95% CI 1.26, 2.23). Risk of nonadherence in the last year of study participation was elevated if, at exit, participants minded wearing during sex (aRR 2.08, 95% CI 1.52, 2.85), during menses (aRR 1.57, 95% CI 1.06, 2.32), reported a problematic change to the vaginal environment (aRR 1.57, 95% CI 1.12, 2.21), and were not “very likely” to use DVR in the future (aRR 1.31, 95% CI 1.02, 1.68). DVR acceptability was overall high yet varied by country. Addressing perceived ring interference with sex, menses, or problematic changes to the vaginal environment in future interventions could help improve adherence, as could embracing sex-positive messaging related to ring use and increased pleasure. Trial Registration ClinicalTrials.gov Identifier: NCT01617096. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10461-021-03205-z. Springer US 2021-03-13 2021 /pmc/articles/PMC8222015/ /pubmed/33713213 http://dx.doi.org/10.1007/s10461-021-03205-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Mayo, Ashley J. Browne, Erica N. Montgomery, Elizabeth T. Torjesen, Kristine Palanee-Phillips, Thesla Jeenarain, Nitesha Seyama, Linly Woeber, Kubashni Harkoo, Ishana Reddy, Krishnaveni Tembo, Tchangani Mutero, Prisca Tauya, Thelma Chitukuta, Miria Gati Mirembe, Brenda Soto-Torres, Lydia Brown, Elizabeth R. Baeten, Jared M. van der Straten, Ariane Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial |
title | Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial |
title_full | Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial |
title_fullStr | Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial |
title_full_unstemmed | Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial |
title_short | Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial |
title_sort | acceptability of the dapivirine vaginal ring for hiv-1 prevention and association with adherence in a phase iii trial |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222015/ https://www.ncbi.nlm.nih.gov/pubmed/33713213 http://dx.doi.org/10.1007/s10461-021-03205-z |
work_keys_str_mv | AT mayoashleyj acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT browneerican acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT montgomeryelizabetht acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT torjesenkristine acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT palaneephillipsthesla acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT jeenarainnitesha acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT seyamalinly acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT woeberkubashni acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT harkooishana acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT reddykrishnaveni acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT tembotchangani acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT muteroprisca acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT tauyathelma acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT chitukutamiria acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT gatimirembebrenda acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT sototorreslydia acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT brownelizabethr acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT baetenjaredm acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT vanderstratenariane acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial AT acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial |